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Background and Objective 
In England, the uptake of direct oral anticoagulants (DOAC) for stroke prevention in atrial fibrillation has been 
slow and varied across different Clinical Commissioning Groups (CCGs). This study aimed to profile the 
prescribing of oral anticoagulants for stroke prevention in patients with atrial fibrillation over three years in a 
CCG without restrictions to DOACs use to understand more about organisational and/or individual barriers to 
the early uptake of DOACs. 
Methods 
Data were collected from nine general practices between 01/04/2012 and 31/03/2015 of patients who were 
initiated on the oral anticoagulant therapy. Data were analysed descriptively and with independent Student’s t 
test and Chi-square test to explore if there was an association between type of oral anticoagulant initiated and 
sex, age, type of prescriber, and prior aspirin use. 
Results 
The early uptake of DOACs significantly increased over the study period (p<0.0001; medium size effect 
φc=0.372). There was no statistically significant difference between gender or age and type of oral anticoagulant 
initiated. Primary care prescribers were responsible for initiating the majority of oral anticoagulants (71%; 
N=257) and driving the use of DOACs (72%, N=71). Patients switched from aspirin to an oral anticoagulant 
were more likely to be initiated on warfarin than DOAC. 
Conclusions 
The early use of DOACs, in a CCG without restrictions to their use, was embraced by primary care prescribers 
in this particular CCG.  
 
Key Points 
The use of direct oral anticoagulants (DOACs) significantly increased over three years in the studied Clinical 
Commissioning Group (CCG) in England. 
The majority of oral anticoagulants were initiated by primary care prescribers, who also were driving the early 













The optimal use of oral anticoagulants (OAC) in patients with atrial fibrillation (AF) can reduce the five-fold 
increased risk of stroke and thus bring benefits to both patients and health and social care systems [1-4]. The use 
of antiplatelet monotherapy (e.g. aspirin) is now discouraged as much greater risk reduction is achieved with 
OAC therapy [5]. Historically, warfarin was the only choice of OAC before the introduction of direct oral 
anticoagulants (DOACs). Although DOACs have their disadvantages, they were shown to be as effective as 
warfarin and overcome some disadvantages of warfarin such as no need of regular coagulation monitoring, 
simpler dosing regimens, and fewer drug or food interactions [5-7].  
In England, DOACs have been recommended by National Institute for Health and Care Excellence (NICE) for 
stroke prevention in non-valvular AF since 2012 (dabigatran in March 2012; rivaroxaban in May 2012; 
apixaban in February 2013; edoxaban in September 2015) but their uptake has been slow [8]. The uptake was 
expected to reach 35% of all OAC prescribing with the release of the updated national guideline for the 
management of AF in 2014 but only 16.5% was achieved in 2015 [8-10]. Additionally, there was a high level of 
unexplained variation across different Clinical Commissioning Groups (CCGs), ranging from 4% to 70% of all 
OAC prescribing [8]. Potentially due to significantly higher unit costs some CCGs managed the introduction of 
DOACs by reserving them after the trial with warfarin [8,11]. In some CCGs, the anticoagulation service was 
commissioned to secondary care and thus limiting initiation of DOACs to secondary care prescribers [12]. 
Restricted use of DOACs has also been observed in treatment centres across Europe [11, 13].  
Little is known about impact of such restrictions on early DOAC use and consequently which type of prescriber 
initiates the therapy, including reasons for selecting warfarin or DOAC. This study aimed to profile the 
prescribing of OAC for stroke prevention in patients with AF over three years in a CCG without restrictions to 
DOAC use to understand more about organisational and/or individual barriers to utilizing DOACs.  
2 Methods 
2.1 Study design and setting 
This retrospective study used primary care prescribing data from 9 General Practitioner (GP) practices in 
Bradford Districts CCG, England. The GP practices had list sizes of up to 10,000 patients and were using TPP-
SystmOne clinical software. The selected CCG comprised of 39 GP practices, serving a local population of over 
300,000 patients. The anticoagulation services were provided by any qualified provider (primary or secondary 
care). Data collected covered a period of 3 years (01/04/2012-31/03/2013, 01/04/2013-31/03/2014, and 
01/04/2014-31/03/2015).  
2.2 Study population 
Adult patients prescribed OAC between 01/04/2012 and 31/03/2015 for stroke prevention in AF were included. 
OACs were warfarin and DOACs (apixaban, dabigatran, rivaroxaban). The DOAC edoxaban was licensed and 
approved by NICE after the study period and thus was not included. 
2.3 Data collection and analysis 
Practice pharmacists ran a pre-defined search on SystmOne to identify all patients who were initiated OAC 
therapy from 01/04/2012 to 31/03/2015. Variables to investigate included age, sex, and type of OAC prescribed. 
The practice pharmacist also manually searched patients’ records to identify: indication for the prescribed OAC; 
who initiated or recommended prescribing it; reason for prescribing DOAC rather than warfarin or vice versa; 
and if the patient was on aspirin prior to OAC therapy. Data were anonymised and entered on a pre-designed 
Excel template before being sent to the research team for analysis. 
Descriptive analysis was conducted and independent Student’s t tests were used to compare continuous 
variables and Chi-square tests were used to test differences in categorical variables. We explored if there was an 
association between type of OAC initiated and sex, age, type of prescriber, and prior aspirin use. All statistical 
analyses were undertaken using SPSS 24 software program.  
3 Results 
3.1 Patient characteristics 
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Five hundred and sixty patients were prescribed OAC. One hundred and thirty-six patients were excluded due to 
non-AF indication (venous thrombosis N=113; mechanical valve N=6; unknown N=17). Out of 424 patients 
with AF indication, 360 patients were new users to the therapy and 64 patients were anticoagulated before the 
study period. 
Characteristics of new patients (N=360) initiated on OAC therapy are summarised in Table 1. Although overall 
more males were anticoagulated, the proportion of females being anticoagulated increased from 43% to 55% 
during the study period (Table 1). There was no statistically significant difference between sex or age and type 
of OAC initiated (p=0.813 and p=0.263). 
3.2 OAC prescribing 
The majority of new patients were initiated on warfarin (73%, N=262) rather than DOAC (27%, N=98) (Table 
1).  However, initiation of DOACs to patients new to OAC therapy significantly increased over time (p<0.0001; 
medium size effect φc=0.372).  
There was no statistically significant difference between the type of prescriber (secondary or primary care) and 
the type of OAC initiated to new patients (p=0.927). Nevertheless, the majority of OAC were initiated by 
primary care prescribers (71%; N=257), who tended to select warfarin (72%, N=186) over DOACs (28%, 
N=71). GPs (92%; N=237) were almost exclusively responsible for initiating OAC therapy in primary care. A 
small proportion was initiated by practice pharmacists (7%; N=18), nurse practitioners (<1%; N=1), or other 
(<1%; N=1). 
Secondary care prescribers accounted for initiating therapy in 27% (N=98) new patients. They also tended to 
select warfarin (73%, N=72) over DOAC (27%, N=26). Cardiology consultants (44%; N=43) were the main 
prescribers, followed by elderly care consultants (25%; N=24), unspecified speciality consultants (21%; N=21), 
stroke consultants (7%; N=7), a general medicine consultant (1%; N=1), a cardiology surgeon (1%; N=1), a 
heart failure nurse (1%, N=1). Prescriber data were missing in 5 (1%) cases. 
Reasons for selecting warfarin over DOAC or vice versa were poorly documented. Only in 2% (N=4) cases of 
patients started on warfarin had a documented reason, which was a patient’s choice. In more cases (49%, N=48) 
information was documented for selecting DOAC over warfarin. Stated reasons included patient’s choice (42%; 
N=41), unable to attend warfarin clinics (4%; N=4), needle-stick phobia (1%; N=1), and drug interaction with 
warfarin (1%; N=1).  
3.3 Switching from aspirin to OAC 
During the study period 39% (N=140) patients new to OAC therapy were switched from aspirin. There was no 
statistically significant difference on which OAC was initiated in these patients (p=0.084). However, majority of 
patients were switched to warfarin (78%, N=109). Primary care prescribers switched majority of patients (76%, 
N=106), which was mainly done by GPs (89%; N=94) and in small number of cases by practice pharmacists 
(10%; N=11) or other (1%; N=1).  
4 Discussion 
In the CCG without restrictions to DOACs use, the initiation of DOACs significantly increased over the three-
year period and majority of OACs, including DOACs, were initiated by primary care prescribers. The observed 
increased use of DOACs correlated with the national prescribing trend of DOACs in the UK [14,15] and was 
likely influenced by guideline changes (e.g. NICE, European Society of Cardiology), changes in Quality and 
Outcome Framework (QOF) incentives for GPs, local and national initiatives to improve anticoagulation in 
patients with AF, and promotion associated with DOACs use [9,15,16]. This CCG was (and remained) well 
above the average use of DOACs in the UK [17], suggesting that no restrictions to DOAC use alongside other 
enablers contributed positively to the uptake of DOACs. 
The main strength of this study was the use of patients’ routine data, and review of patients’ primary care 
medical records. This allowed us to collect information otherwise unavailable on prescribing databases (e.g. 
who initiated the therapy, reasons for choosing a particular OAC) and gain greater insight into early DOAC 
prescribing. However, several limitations should be taken into account. The data used in the study was collected 
from GP practices from a single CCG, thus our findings may not be generalisable. Lack of diagnostic 
information limited data analysis and thus insight into appropriateness of OAC use.  
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Evidence about which prescribers initiate OAC therapy (i.e. primary or secondary care prescriber) is needed to 
promote the optimal and rational use of DOACs but is currently limited. Patients with AF are predominantly 
managed in primary care setting and thus primary care prescribers are in the best position to identify patients 
with undiagnosed AF and undertreated with OAC therapy. Our study showed that 71% of new OAC 
prescriptions were solely initiated by primary care prescribers, predominantly GPs. In contrast, a Danish OAC 
utilization study using the prescribing data (August 2011 to June 2013) showed that hospital prescribers initiated 
vitamin K antagonists and DOACs therapy in 57% and 74% of cases respectively [18]. In contrast with the 
Danish study [18] we observed that primary care physicians in the studied CCG were embracing the use of 
DOACs as 72% of new DOACs prescriptions were solely initiated by primary care prescribers. This finding also 
differs from prescribing trends seen in Canada [19] and USA [20], where secondary care physicians seem to 
drive the uptake of DOACs. Additionally, while in the studied CCG, between 2014 and beginning of 2015, 
DOACs were the predominant OAC initiated by primary care prescribers, in Canada it was warfarin. Further 
research should explore how embracing use of DOACs in primary care contributes to the overall uptake of 
DOACs. 
The proportion of females initiated on OACs increased during the study period. This was not surprising and 
could be attributed to the change in the AF-related stroke risk calculation, moving from the CHADS2 to 
CHA2DS2-VASc score. This meant that female patients aged 65 and over were candidates for the OAC therapy 
[9]. The use of DOACs between sexes was similar, which supports the close to even split reported by Loo et al. 
(2017) in their study of DOAC prescribing in primary care in the UK [14]. However, with increasing uptake of 
DOACs in the UK, further studies could re-evaluate if DOAC use varies between sexes, and if so reasons 
behind it. 
In this study, the limited evidence available suggests that when patients started on DOAC rather than warfarin, 
they were more likely to be involved in the decision-making, possibly due to being presented with different 
therapy choices. Previous evidence seems to corroborate that the uptake of DOACs increases if patients are 
involved in decisions about their anticoagulation therapy [21-23]. While a systematic review showed that 
patients who were not involved in these decisions were prescribed warfarin [23], two quantitative studies have 
shown that patients prescribed DOAC were more likely to be involved in the decision-making and presented 
with several therapy options [21,22]. It seems that patient involvement in the decision-making about their 
anticoagulation therapy may enable the grater uptake of DOACs. Therefore, this further strengthens why 
consultations should move from being paternalistic and involve patients in meaningful discussions about their 
treatment options. 
To our knowledge, our study is the only study exploring on which OAC (warfarin or DOAC) the patient with 
prior aspirin monotherapy will be initiated. In this study, 140 patients were switched from aspirin to OAC 
therapy. This was expected as the use of antiplatelet monotherapy for stroke prevention has declined over years 
due to greater evidence for OAC use [9,15,24,25]. It is interesting that more patients were moved from therapy 
without monitoring (i.e. aspirin) to therapy requiring regular monitoring (i.e. warfarin) rather than without 
regular monitoring (i.e. DOAC). This may be due to lack of patient involvement in the decision-making as we 
have observed with warfarin initiation but requires further exploration. 
5 Conclusions 
This study has demonstrated that the early uptake of DOACs was embraced by primary care prescribers in this 
particular CCG, although findings cannot be generalised. Future, bigger studies with data from multiple CCGs 
will allow for an in-depth investigation of whether these findings are representative nationally, as well as 
providing a glimpse of reasons why the early uptake of DOACs may be higher in certain areas and lower in 
others. Future studies investigating the barriers and enablers to the uptake of DOAC in the UK will also provide 
understanding of how to increase uptake and promote optimal and rational use of these medicines in both 
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Table 1.  1 
Demographics of new patients initiated on oral anticoagulant therapy between 1/04/2012 and 31/03/2015.  2 
  1/4/2012-31/3/2013 1/4/2013-31/3/2014  1/4/2014-31/3/2015  TOTAL 
 Initiated on 
warfarin  























warfarin or DOAC 
N (%) 
Total 119 11 85 32 58 55 262 98 360  
Age (years)*   
Mean ±SD 77±11 75±7 76±9 78±10 72±12 79±11 76±11 78±10 76±11 
<65 16 (13) 2 (18) 12 (14) 2 (6) 15 (26) 6 (11) 43 (16) 10 (10) 53 (15) 
65-74 26 (22) 1 (9) 26 (31) 6 (19) 14 (24) 12 (22) 66 (25) 19 (19) 85 (24) 
75-84 46 (39) 8 (73) 32 (38) 14 (44) 20 (35) 19 (34) 98 (37) 41 (42) 139 (39) 
85-90 21 (18) 0 (0) 11 (13) 8 (25) 6 (10) 7 (13) 38 (15) 15 (15) 53 (15) 
>90 10 (8) 0 (0) 4 (5) 2 (6) 3 (5) 11 (20) 17 (7) 13 (13) 30 (8) 
Sex     
Male   66 (55) 8 (73) 48 (56) 17 (53) 26 (45) 26 (47) 140 (53) 51 (52) 191 (53) 
Female 53 (45) 3 (27) 37 (44) 15 (47) 32 (55) 29 (53) 122 (47) 47 (48) 169 (47) 
SD standard deviation, DOACs direct oral anticoagulants. 3 
